Doni Bloomfield, JD; Elvira D鈥橝ndrea, MD, MPH; Sarosh Nagar; et al.
free access
JAMA Oncol. 2022;8(4):537-545. doi:10.1001/jamaoncol.2021.7230
This systematic review and meta-analysis examines the design of cancer biosimilar efficacy studies compared with the reference drug pivotal trials and provides summary risk ratio estimates for each cancer type drug subgroup.
Nicholas J. Vogelzang, MD; Tomasz M. Beer, MD; Winald Gerritsen, MD; et al.
free access
JAMA Oncol. 2022;8(4):546-552. doi:10.1001/jamaoncol.2021.7298
This randomized clinical trial evaluates the efficacy and safety of DCVAC/PCa plus chemotherapy followed by DCVAC/PCa maintenance treatment in patients with metastatic castration-resistant prostate cancer.
Guo-Ying Liu, MD; Wang-Zhong Li, MD; De-Shen Wang, MD; et al.
free access
JAMA Oncol. 2022;8(4):553-561. doi:10.1001/jamaoncol.2021.7366
This randomized clinical trial investigates the efficacy and safety of capecitabine maintenance therapy for patients with newly diagnosed metastatic nasopharyngeal carcinoma who had achieved disease control after induction chemotherapy.
Alexander V. Louie, MD, PhD; Patrick V. Granton, PhD; Alysa Fairchild, MD; et al.
open access
JAMA Oncol. 2022;8(4):562-568. doi:10.1001/jamaoncol.2021.7664
This randomized clinical trial compares the use of esophageal-sparing intensity-modulated radiotherapy with standard palliative radiotherapy in patients with incurable non鈥搒mall cell lung cancer.
Ryan D. Nipp, MD, MPH; Nora K. Horick, MS; Carolyn L. Qian, BA; et al.
free access
JAMA Oncol. 2022;8(4):571-578. doi:10.1001/jamaoncol.2021.7643
This nonblinded randomized clinical trial compares the effects of a symptom monitoring intervention vs usual care on symptom burden and health care use among hospitalized adult patients with advanced cancer.
Gelareh Sadigh, MD; Robert J. Gray, PhD; Joseph A. Sparano, MD; et al.
free access
has audio
JAMA Oncol. 2022;8(4):579-586. doi:10.1001/jamaoncol.2021.7656
This post hoc analysis of a randomized clinical trial examines the recurrence and survival rates in women with breast cancer of differing racial and sociodemographic groups.
-
Podcast:
Racial Disparity in Survival Outcomes for Early Hormone Receptor鈥揚ositive Breast Cancer
Kathryn P. Lowry, MD; H. Amarens Geuzinge, MSc; Natasha K. Stout, PhD; et al.
free access
JAMA Oncol. 2022;8(4):587-596. doi:10.1001/jamaoncol.2021.6204
This decision analytical study uses microsimulation models from the Cancer Intervention and Surveillance Modeling Network to estimate the benefits and harms associated with breast cancer screening strategies using mammography and magnetic resonance imaging at various start ages for women with ATM, CHEK2, and PALB2 pathogenic variants.
Wei Fang Dai, MPH; Jaclyn M. Beca, MSc; Chenthila Nagamuthu, MPH; et al.
free access
JAMA Oncol. 2022;8(4):597-606. doi:10.1001/jamaoncol.2021.8049
This economic evaluation examines the cost-effectiveness of pertuzumab, trastuzumab, and chemotherapy vs trastuzumab and chemotherapy for patients with metastatic breast cancer.